Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients

Projektinformationen

XTremedy Medical

ID Finanzhilfevereinbarung: 101069625

DOI

10.3030/101069625

Projekt abgeschlossen

EK-Unterschriftsdatum 20 Juni 2022

Startdatum 1 Juli 2022

Enddatum 31 Dezember 2022

Finanziert unter

• European innovation ecosystems

Gesamtkosten

Keine Daten

EU-Beitrag

€ 75 000,00

Koordiniert durch

XTREMEDY MEDICAL LIMITED
Ireland

Periodic Reporting for period 1 - XTremedy Medical (Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients)

Berichtszeitraum: 2022-07-01 bis 2022-12-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

XTremedy Medical are a surgical device company developing treatments for infected wounds, in particular Diabetic Foot Ulcers (DFUs). Infection has now been recognised as a leading cause of wound chronicity - wounds that do not respond to initial treatments.i Infections that spread to deep muscle and bone tissues, are the leading cause of amputations in diabetics. Biofilms, a type of infection often found in wounds, are complex to treat with up to 1000-fold tolerance to antibiotics.ii High concentrations of antibiotics required to treat these infections impairs kidney function and leads to high rates of kidney failure.
XTremedy Medical overcomes limitations with current solutions by treating both surface and subsurface tissues without disrupting tissue structures. XTremedy’s first device – BioBlate, is a non-thermal ablation device using pulsed electric field ablation (PFA) to treat biofilms. PFA is known for its anti-microbial and non-destructive properties.
Incorporating BioBlate technology enables the surgeon to remove all biofilm within the wound without removing excess healthy tissue which impairs healing. Delivering wound margins free of biofilm leads to fewer surgeries and shortened hospital stays

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Commercialisation (regulatory and market access) strategy mapped for BioBlate technology

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Xtremedy have demonstrated that thier PFA device is up to 1000x more effective at removing biofilm/bioburden than the standard of care (saline flush). Using the BioBlate device, the team achieved 6 log reductions in ex-vivo staph epidermis biofilms and 4 log reductions in staph aureus. This is compared to <1 log reduction with the standard of care, a saline flush. These results have been validated in a third party lab.